8-OH-PBZI je lek koji se koristi u naučnim istraživanjima. On deluje kao potentan i selektivan agonist dopaminskog D3 receptora.[1][2][3]

8-OH-PBZI
IUPAC ime
(3aS,9bR)-3-propil-1,2,3a,4,5,9b-heksahidrobenzo[e]indol-8-ol
Identifikatori
ATC kodnone
PubChemCID 10353845
ChemSpider8529297 ДаY
Hemijski podaci
FormulaC15H21NO
Molarna masa231,333 g/mol
  • CCCN1CC[C@H]2[C@@H]1CCC3=C2C=C(C=C3)O
  • InChI=1S/C15H21NO/c1-2-8-16-9-7-13-14-10-12(17)5-3-11(14)4-6-15(13)16/h3,5,10,13,15,17H,2,4,6-9H2,1H3/t13-,15+/m1/s1 ДаY
  • Key:LJDRQPOQHHOXHM-HIFRSBDPSA-N ДаY

Reference уреди

  1. ^ Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N; Crider, AM (1997). „The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain”. European journal of pharmacology. 339 (2–3): 261—70. PMID 9473144. doi:10.1016/S0014-2999(97)01372-1. 
  2. ^ Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). „Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI”. European journal of pharmacology. 342 (2–3): 153—61. PMID 9548380. doi:10.1016/S0014-2999(97)01494-5. 
  3. ^ Malik, P; Andersen, MB; Peacock, L (2004). „The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia”. Pharmacology, biochemistry, and behavior. 78 (4): 805—10. PMID 15301939. doi:10.1016/j.pbb.2004.05.019.